Domestic pharmaceutical companies are keeping eyes on gigantic hepatitis B drugs to catch the right moment
Domestic pharmaceutical companies in Korea have concentrated on launches of follow-up drugs for Baraclude(BMS) and Viread(Gilead), which divide the hepatitis B drug market into two parts.
Baraclude is in the state where domestic pharmaceutical companies already completed developing its generic d...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
